Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
Cancer immunotherapy such as anti-PD-1/anti-PD-L1 immune checkpoint blockade (ICB) can provide significant clinical benefit in patients with advanced malignancies. However, most patients eventually develop progressive disease, thus necessitating additional therapeutic options. We have developed a no...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1057702/full |
| _version_ | 1797900427597971456 |
|---|---|
| author | William L. Redmond Melissa J. Kasiewicz Emmanuel T. Akporiaye |
| author_facet | William L. Redmond Melissa J. Kasiewicz Emmanuel T. Akporiaye |
| author_sort | William L. Redmond |
| collection | DOAJ |
| description | Cancer immunotherapy such as anti-PD-1/anti-PD-L1 immune checkpoint blockade (ICB) can provide significant clinical benefit in patients with advanced malignancies. However, most patients eventually develop progressive disease, thus necessitating additional therapeutic options. We have developed a novel agent, a-TEA-LS, that selectively induces tumor cell death while sparing healthy tissues, leading to increased activation of tumor-reactive T cells and tumor regression. In the current study, we explored the impact of combined a-TEA-LS + ICB in orthotopic and spontaneously arising murine models of mammary carcinoma. We found that a-TEA-LS + ICB led to increased production of pro-inflammatory cytokines that were associated with a reduction in tumor growth and prolonged survival. Together, these data demonstrate the potential utility of a-TEA-LS + ICB for the treatment of breast cancer and provide the rationale for clinical translation of this novel approach. |
| first_indexed | 2024-04-10T08:44:44Z |
| format | Article |
| id | doaj.art-69e74ec327b245408fec86858ad9157e |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T08:44:44Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-69e74ec327b245408fec86858ad9157e2023-02-22T09:05:52ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-02-011410.3389/fimmu.2023.10577021057702Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEAWilliam L. Redmond0Melissa J. Kasiewicz1Emmanuel T. Akporiaye2Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, United StatesEarle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, United StatesVeana Therapeutics, Portland, OR, United StatesCancer immunotherapy such as anti-PD-1/anti-PD-L1 immune checkpoint blockade (ICB) can provide significant clinical benefit in patients with advanced malignancies. However, most patients eventually develop progressive disease, thus necessitating additional therapeutic options. We have developed a novel agent, a-TEA-LS, that selectively induces tumor cell death while sparing healthy tissues, leading to increased activation of tumor-reactive T cells and tumor regression. In the current study, we explored the impact of combined a-TEA-LS + ICB in orthotopic and spontaneously arising murine models of mammary carcinoma. We found that a-TEA-LS + ICB led to increased production of pro-inflammatory cytokines that were associated with a reduction in tumor growth and prolonged survival. Together, these data demonstrate the potential utility of a-TEA-LS + ICB for the treatment of breast cancer and provide the rationale for clinical translation of this novel approach.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1057702/fullimmune checkpoint blockadePD-1PD-L1T cellsalpha-TEA |
| spellingShingle | William L. Redmond Melissa J. Kasiewicz Emmanuel T. Akporiaye Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA Frontiers in Immunology immune checkpoint blockade PD-1 PD-L1 T cells alpha-TEA |
| title | Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA |
| title_full | Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA |
| title_fullStr | Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA |
| title_full_unstemmed | Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA |
| title_short | Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA |
| title_sort | enhancement of anti tumor efficacy of immune checkpoint blockade by alpha tea |
| topic | immune checkpoint blockade PD-1 PD-L1 T cells alpha-TEA |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1057702/full |
| work_keys_str_mv | AT williamlredmond enhancementofantitumorefficacyofimmunecheckpointblockadebyalphatea AT melissajkasiewicz enhancementofantitumorefficacyofimmunecheckpointblockadebyalphatea AT emmanueltakporiaye enhancementofantitumorefficacyofimmunecheckpointblockadebyalphatea |